The effectiveness of ezetimibe and atorvastatin combination therapy related to low density cholesterol goal levels attainment in patients with acute coronary syndromes

Abstract

The use of statins is essential for aggressive lipid-lowering treatment in acute he use of statins is essential for aggressive lipid-lowering treatment in acute coronary syndrome (ACS) patients. The purpose of the present study was to oronary syndrome (ACS) patients. The purpose of the present study was to examine the impact of ezetimibe, a selective intestinal cholesterol transporter xamine the impact of ezetimibe, a selective intestinal cholesterol transporter inhibitor, in ACS patients. We conducted a 16-week one-center, prospective, nhibitor, in ACS patients. We conducted a 16-week one-center, prospective, randomized, and open-label clinical trial, involving 323 patients who had been andomized, and open-label clinical trial, involving 323 patients who had been hospitalized for an acute coronary syndrome ospitalized for an acute coronary syndrome within the preceding 14 days. They were received atorvastatin 20 mg during 28 ithin the preceding 14 days. They were received atorvastatin 20 mg during 28 days and after those 292 patients, who had low density cholesterol (LDL-C) lev- ays and after those 292 patients, who had low density cholesterol (LDL-C) levels ≥1.81 mmol/L, were randomized to ezetimibe 10 mg/day co-administered 1.81 mmol/L, were randomized to ezetimibe 10 mg/day co-administered with atorvastatin therapy (EZE + Statin) or doubling their current atorvastatin ith atorvastatin therapy (EZE + Statin) or doubling their current atorvastatin dose. The primary ef ose. The primary efficacy end point was absolute reduction in LDL-C for eze- cacy end point was absolute reduction in LDL-C for ezetimibe plus atorvastatin versus atorvastatin-monotherapy treatment groups. At imibe plus atorvastatin versus atorvastatin-monotherapy treatment groups. At 16 weeks, the mean LDL cholesterol level during the study was 1.60 mmol per 6 weeks, the mean LDL cholesterol level during the study was 1.60 mmol per liter in the atorvastatine-ezetimibe group, as compared with 1.91 mmol per liter iter in the atorvastatine-ezetimibe group, as compared with 1.91 mmol per liter in the atorvastatin-monotherapy group (P<0.001). Patients receiving ezetimibe n the atorvastatin-monotherapy group (P<0.001). Patients receiving ezetimibe and statin were more likely to achieve target LDL-C after 16 weeks compared to nd statin were more likely to achieve target LDL-C after 16 weeks compared to patients doubling their statin dose. Ezetimibe/statin combination therapy was atients doubling their statin dose. Ezetimibe/statin combination therapy was well tolerated among this ACS patients, without safety concerns.